Drug Trial Radar · NCT02405104
Chlorzoxazone in Hip and Knee Arthroplasty
Last checked: Nov 20, 2026Latest source record: Sep 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Sep 1, 2015
Primary completion
Dec 31, 2017
Study completion Jul 31, 2019
Sponsor
- Lead sponsor
- Northern Orthopaedic Division, DenmarkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to elucidate whether patients operated with THA and TKA can benefit from treatment with chlorzoxazone.
Conditions
- Osteoarthritis of Hip
- Osteoarthritis, Knee
Interventions
chlorzoxazoneDrug
ATC-code: M03BB03
PlaceboDrug
Placebo
THAProcedure
Surgical treatment of osteoarthrosis in the hip, by replacement.
TKAProcedure
Surgical treatment of osteoarthrosis in the knee, by replacement.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain after 5 meter walkTime frame: 24 hours post OP
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northern Orthopaedic Division, Clinic Farsø, Aalborg University Hospital
Farsø, Northern Jutland, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.